| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 27 | |
| #2 | EPO (European Patent Office) | 20 | |
| #3 | Australia | 11 | |
| #4 | WIPO (World Intellectual Property Organization) | 8 | |
| #5 | Canada | 5 | |
| #6 | Hong Kong | 5 | |
| #7 | China | 4 | |
| #8 | Hungary | 4 | |
| #9 | Republic of Korea | 4 | |
| #10 | Mexico | 4 | |
| #11 | Serbia | 4 | |
| #12 | Japan | 3 | |
| #13 | New Zealand | 3 | |
| #14 | South Africa | 3 | |
| #15 | EAPO (Eurasian Patent Organization) | 2 | |
| #16 | Brazil | 1 | |
| #17 | Singapore | 1 | |
| #18 | Slovenia | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Environmental technology | |
| #4 | Organic fine chemistry | |
| #5 | Medical technology |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Therapeutic chemical compounds | |
| #3 | Peptides | |
| #4 | Climate change adaptation technologies | |
| #5 | Microorganisms | |
| #6 | Fermentation | |
| #7 | Measuring microorganism processes | |
| #8 | Combinatorial chemistry | |
| #9 | Sugars | |
| #10 | Object sterilising |
| # | Name | Total Patents |
|---|---|---|
| #1 | Schlegl Robert | 50 |
| #2 | Lundberg Urban | 41 |
| #3 | Meinke Andreas | 33 |
| #4 | Weber Michael | 27 |
| #5 | Hanner Markus | 24 |
| #6 | Schüler Wolfgang | 24 |
| #7 | Wizel Benjamin | 24 |
| #8 | Reinisch Christoph | 20 |
| #9 | Grohmann Brigitte | 19 |
| #10 | Wruss Jürgen | 17 |
| Publication | Filing date | Title |
|---|---|---|
| WO2021048221A1 | Inactivation process for viruses | |
| JP2019163310A | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof | |
| EP3609911A1 | Multivalent ospa polypeptides and methods and uses relating thereto | |
| JP2017149728A | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof | |
| AU2016375338A1 | Zika virus vaccine | |
| WO2016193402A1 | Pseudomonas vaccine | |
| US2016114033A1 | Aluminum compounds for use in therapeutics and vaccines | |
| EP3564257A1 | Mutant fragments of ospa and methods and uses relating thereto | |
| WO2014044690A1 | Improved vaccines | |
| EP3689372A1 | Mutant fragments of ospa and methods and uses relating thereto | |
| EP1347775A2 | Uses for polycationic compounds as vaccine adjuvants |